General Aspects of Thrombocytopenia, Platelet Transfusions, and Thrombopoietic Growth Factors

David J. Kuter

DOI: https://doi.org/10.1016/b978-0-323-46202-0.00007-8

2019-01-01

Abstract:Thrombocytopenia is a common clinical problem. Patients with platelet counts below 10,000 may have an increased risk of spontaneous bleeding, and those with platelet counts below 50,000 may have bleeding complications with surgery. Aside from the risk of bleeding, thrombocytopenia of any degree may be the major presenting feature of a wide variety of diseases including myelodysplastic syndrome, immune thrombocytopenia (ITP), autoimmune disorders, and infection. In general, thrombocytopenia is attributed to either reduced platelet production, increased platelet destruction, or increased platelet sequestration. Platelet production can be reduced by many drugs (e.g., antiviral agents) or disorders (e.g., myelodysplasic syndrome [MDS]) that prevent bone marrow stem cells from generating bone marrow megakaryocytes, or prevent megakaryocytes from then shedding platelets. Platelet destruction may occur from increased consumption by coagulation disorders (e.g., thrombotic thrombocytopenic purpura [TTP]) or increased immune clearance (e.g., ITP). Splenomegaly can increase platelet sequestration. There are several key aspects in the evaluation of the thrombocytopenic patient. A careful history helps reveal the chronicity of the low platelet count as well as prior bleeding episodes and new medications or infection. Physical examination may find adenopathy and splenomegaly. Evaluation of the peripheral blood smear is essential to assess platelet number, size, and granularity as well as the presence of abnormal red and white blood cells indicative of other underlying disorders. It is always vital to assess for pseudothrombocytopenia, TTP, hemolytic-uremic syndrome, disseminated intravascular coagulation and ITP. If possible, treatment of the underlying cause should alleviate the thrombocytopenia, but some patients may need to be supported with platelet transfusions and sometimes with thrombopoietic growth factors.